Skip to content
Screener

AbCellera Biologics Inc. ABCL Q1 2025 earnings

Reported May 8, 2025 · After market close

Revenue$4.2MMiss by $3.1M
EPS-$0.15Beat by $0.02
Revenue estimate$7.3M
EPS estimate-$0.17

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$5.3M
EPS estimate-$0.18

Financials

Q1 2025

Income statement

See full
Revenue$4.2M-57.5%
Operating income-$62.7M-14.1%
Net income-$45.6M-12.3%
EPS (diluted)-$0.15-7.1%

Balance sheet

See full
Cash & equivalents$184.3M+24.0%
Total debt$67.8M-7.8%
Total equity$1.0B-9.5%
Total assets$1.3B-8.1%

Cash flow

See full
Operating cash flow-$11.6M+72.3%
CapEx$10.6M-55.9%
Free cash flow-$22.2M+66.3%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$664.51M-49.9%
Enterprise value$548.09M-56.2%
P/S28.7×-8.3×

Profitability

See full
Operating margin-1,395.3%-8,455pp
Net margin-726.2%+2,421pp
FCF margin-619.9%+1,749pp

Returns & leverage

See full
Return on equity-15.6%+5.0pp
Debt / equity0.1×0.0×
Current ratio10.1×+2.4×

Segments

By geography

See full
Canada$16.0M+144%
United States$2.8M+311%

By product

See full
Research fees$4.1M-58.4%

FAQ

When did AbCellera Biologics Inc. report Q1 2025 earnings?
AbCellera Biologics Inc. (ABCL) reported Q1 2025 earnings on May 8, 2025 after market close.
What were AbCellera Biologics Inc.'s Q1 2025 revenue and EPS?
AbCellera Biologics Inc. reported revenue of $4.2M and eps of $-0.15 for Q1 2025.
Did AbCellera Biologics Inc. beat estimates in Q1 2025?
Revenue missed the consensus estimate of $7.3M by $3.1M. EPS beat the consensus estimate of $-0.17 by $0.02.
How did AbCellera Biologics Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 57.5% from $10.0M a year earlier and eps declined 7.1% from $-0.14.
Where can I find AbCellera Biologics Inc.'s Q1 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-023808) and the 10-Q periodic report (0001628280-25-023836) directly on SEC EDGAR. The filing index links above go to sec.gov.